Jazz Pharmaceuticals Plc - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed on January 8, 2013, by Jazz Pharmaceuticals Plc, an Ireland-based pharmaceutical company. The report discloses a corporate overview and financial update presented at the J.P. Morgan Healthcare Conference in San Francisco on the same date.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a notification that such financial information and updated guidance were presented in a separate exhibit (Exhibit 99.1) and via a public webcast.
Material Changes and Guidance
The primary purpose of this filing is to disclose an update to the Company's financial guidance for the fiscal year ended December 31, 2012. This guidance was originally provided on November 8, 2012. The filing references a transcript and presentation slides containing the specific details of these changes and additional financial information.
Risks and Contingencies
The filing includes a standard disclaimer stating that the information contained in Item 2.02 and Exhibit 99.1 is not deemed "filed" under Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated by reference into any other SEC filings. No specific operational risks or legal contingencies are detailed within the text of this 8-K form.
Investor Verification Checklist
- Review Exhibit 99.1 (transcript and slides) for the specific updated financial guidance for the year ended December 31, 2012.
- Compare the new guidance figures against the previous guidance issued on November 8, 2012.
- Verify the specific drivers for any changes in revenue or expense projections mentioned in the presentation.
- Confirm the availability of the audio webcast and presentation materials on the Company's website.